Ozempic for Prediabetes: FDA Indications, STEP-1 Data & DPP First-Line Review

This YMYL evidence review is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Roughly 98 million US adults have prediabetes— about 38% of the adult population, per the CDC — and a growing share are asking their prescriber for Ozempic to prevent progression to type 2 diabetes. The reality is more nuanced than the headlines: Ozempic is FDA-approved for type 2 diabetes, not for prediabetes. The same active molecule — semaglutide — is FDA-approved at a higher dose (2.4 mg weekly) under the brand name Wegovy for chronic weight management in adults who meet the BMI criteria. Many prediabetic adults qualify for Wegovy on the obesity indication. This article separates what the FDA labels actually say from what off-label prescribing looks like in practice, anchors the Diabetes Prevention Program as the gold-standard first-line intervention, and walks through the cost and insurance reality.

Is Ozempic FDA-approved for prediabetes? (No)

The Ozempic prescribing information on DailyMed lists exactly two FDA-approved indications^[10]:

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease.

Prediabetes does not appear in the indications section. The label further specifies that Ozempic is not indicated for type 1 diabetes and has not been studied in patients with a history of pancreatitis. There is no carve-out, footnote, or supplemental indication for prediabetes, impaired glucose tolerance, impaired fasting glucose, or elevated HbA1c that has not crossed the T2D diagnostic threshold.

Prescribing Ozempic specifically for prediabetes therefore constitutes off-label use. Off-label prescribing is legal in the United States — the FDA regulates drug marketing, not the practice of medicine — and physicians may prescribe an approved drug for an unapproved indication when clinically justified. What off-label prescribing does not guarantee is insurance coverage. Commercial pharmacy benefit managers and Medicare Part D plans build formulary coverage rules around the FDA-approved indication, and a prescription written with a prediabetes diagnosis code (ICD-10 R73.03) will almost always be denied for Ozempic.

A separate fact people occasionally conflate: semaglutide as a molecule is FDA-approved for prediabetes-adjacent populations under the Wegovy brand. But that approval is for chronic weight management, not for prediabetes itself, and the qualifying criterion is BMI plus comorbidity, not glycemic status. The same molecule, the same manufacturer, two separate FDA approvals at two different doses with two different commercial wrappers. See the head-to-head Wegovy vs Ozempic evidence review for the regulatory and dosing differences in detail.

Why Wegovy may be the right semaglutide product

If you have prediabetes and your BMI is 30 or above, or 27 or above with at least one weight-related comorbidity, Wegovy is the on-label semaglutide product. The FDA-approved indication for Wegovy reads, in essence^[11]:

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus).

The italicized list of weight-related comorbidities in the prescribing information is illustrative, not exhaustive. Many prescribers will document prediabetes itself as a qualifying weight-related comorbidity for the BMI 27-29.9 bracket, alongside the more frequently-cited hypertension, dyslipidemia, obstructive sleep apnea, and non-alcoholic fatty liver disease. For prediabetic adults with a BMI of 30 or above, no comorbidity is needed; obesity itself is the qualifying criterion.

Mechanistically Wegovy and Ozempic are the same drug. The active ingredient is semaglutide, a 31-amino-acid GLP-1 receptor agonist analogue manufactured by Novo Nordisk in the same prefilled-pen format. What separates them are the FDA-approved indication, the maximum dose (2.4 mg weekly for Wegovy versus 2.0 mg weekly for Ozempic), and the insurance reality that flows from the indication. For a prediabetic patient with qualifying obesity, the on-label path is to fill a Wegovy prescription written under the chronic weight management indication, not an Ozempic prescription written off-label.

The Diabetes Prevention Program — gold-standard first-line

Before the GLP-1 conversation begins, the highest-quality evidence base for preventing progression from prediabetes to type 2 diabetes is the Diabetes Prevention Program (DPP) lifestyle intervention. The DPP was a landmark NIH-funded randomized controlled trial published in the New England Journal of Medicine by Knowler and colleagues in 2002^[1].

The DPP randomized 3,234 adults with prediabetes (impaired fasting glucose plus impaired glucose tolerance) to three arms: an intensive lifestyle intervention targeting at least 7% body-weight reduction and 150 minutes per week of moderate physical activity; metformin 850 mg twice daily; or placebo. Over a mean 2.8-year follow-up:

• Lifestyle intervention reduced T2D incidence by 58% versus placebo (95% CI 48-66%).
• Metformin reduced T2D incidence by 31% versus placebo (95% CI 17-43%).
• Lifestyle beat metformin head-to-head as a first-line intervention.

The DPPOS follow-up (Knowler 2009, Lancet) tracked the original cohort for an additional decade^[2]. At 10 years, diabetes incidence remained reduced by 34% in the original lifestyle arm and 18% in the original metformin arm versus the placebo arm. The lifestyle benefit was durable a decade out, even though the trial-protocol structured intervention ended at year three. That durability is the strongest part of the DPP evidence base — behavior change measured ten years later still moved the diabetes-incidence needle.

The DPP curriculum is now disseminated nationally as the CDC-recognized National Diabetes Prevention Program. It is a year-long structured group program (typically 16 weekly core sessions followed by monthly maintenance), delivered in person or via approved virtual platforms, and is covered without cost-sharing by Medicare (the Medicare Diabetes Prevention Program benefit) and by most commercial insurance plans. The CDC maintains a registry of recognized providers at cdc.gov/diabetes-prevention. For prediabetic adults, this is the first-line intervention by any major clinical practice guideline (American Diabetes Association, American Association of Clinical Endocrinology, USPSTF), and it is the comparator against which any pharmacologic option for prediabetes is properly judged.

STEP-1 post-hoc data: Wegovy + progression-to-T2D

Wegovy (semaglutide 2.4 mg weekly) was approved on the strength of the STEP-1 trial^[3]. STEP-1 randomized 1,961 adults with overweight or obesity but without type 2 diabetes to once-weekly semaglutide 2.4 mg or placebo, with a lifestyle background, for 68 weeks. Mean body-weight reduction was −14.9% on semaglutide versus −2.4% on placebo (treatment-regimen estimand). About 32% of semaglutide-treated patients reached at least 20% body-weight reduction.

STEP-1 was not a diabetes-prevention trial. Its primary endpoints were percent body-weight change and the proportion of patients achieving at least 5% body-weight loss. A large subset of STEP-1 enrollees had baseline prediabetes, however, and a post-hoc pooled analysis of STEP-1, STEP-3, and STEP-4 by Perreault and colleagues in Diabetes Care (2022) examined what happened to their glycemic status on semaglutide 2.4 mg^[4].

The Perreault post-hoc analysis reported that, at week 68:

• 84.1% of semaglutide-treated participants with baseline prediabetes shifted to normoglycemia, versus 47.8% on placebo (the placebo arms still got lifestyle counseling).
• New-onset type 2 diabetes was rare in both arms because the trials only ran 68 weeks; the analysis emphasized the prediabetes-to-normoglycemia transition as a near-term proxy for progression risk.
• The signal is consistent with the body-weight-reduction mechanism: substantial weight loss improves insulin sensitivity and reduces hepatic glucose output, which is the same physiology that drives the DPP lifestyle benefit.

The honest read on this evidence is twofold. Yes, Wegovy in prediabetic adults with overweight or obesity drove a substantial shift to normoglycemia at 68 weeks. But this is post-hoc, hypothesis-generating evidence, not a dedicated diabetes-prevention trial with a primary progression-to-T2D endpoint, the longer follow-up needed to measure incidence, and a regulatory submission to the FDA. As of the 2026 label, Wegovy does not carry a diabetes-prevention indication. Patients should understand that the evidence supporting Wegovy for the prediabetes use case is real but secondary to the on-label chronic weight management evidence.

STEP-2 separately tested semaglutide 2.4 mg in adults who already had type 2 diabetes plus BMI 27 or above, and reported mean body-weight reduction of −9.6% versus −3.4% placebo at 68 weeks^[5]. The T2D population responds to GLP-1 weight-loss therapy at a lower magnitude than the non-diabetic population — one of the reasons earlier intervention (during prediabetes) is mechanistically attractive but evidentiarily under-built.

Off-label prescribing of Ozempic for prediabetes

Off-label Ozempic prescriptions for prediabetes do exist, but they sit in a different regulatory and commercial reality than on-label Ozempic for type 2 diabetes or on-label Wegovy for chronic weight management. What that looks like in practice:

• Legality. Off-label prescribing is legal in the United States. A licensed prescriber may prescribe Ozempic to a prediabetic patient when clinically justified. The FDA regulates drug marketing — including manufacturer promotion of unapproved uses — rather than the practice of medicine.
• Manufacturer promotion is barred. Novo Nordisk may not market Ozempic for prediabetes, may not include prediabetes in patient or prescriber education materials, and may not provide off-label-use samples or coupons. Any reference you encounter to “Ozempic for prediabetes” in Novo Nordisk materials would be a labeling violation.
• Insurance coverage will almost certainly be denied. Commercial PBMs and Medicare Part D maintain coverage rules tied to the on-label diagnosis code. An Ozempic claim submitted with ICD-10 R73.03 (prediabetes) or R73.09 (other abnormal glucose) is denied at the pharmacy benefit step. A claim submitted with E11.x (type 2 diabetes) when the patient does not actually have T2D would be insurance fraud.
• Self-pay is the practical access path. NovoCare Pharmacy lists Ozempic at $499 per month for self-pay patients, regardless of diagnosis. Retail without manufacturer programs runs near $1,349 per month list price. Some compounded semaglutide remains available through 503A pharmacies for medical-necessity carve-outs (allergies to commercial-product excipients, specific personalization needs), but the broad FDA-shortage compounding pathway closed in early 2025.
• Side-effect profile is the same. Ozempic and Wegovy share the GLP-1 receptor agonist class effect: nausea, vomiting, diarrhea, constipation, and the FDA boxed warning for thyroid C-cell tumor risk based on rodent studies. There is no safety reason to favor off-label Ozempic over on-label Wegovy for a prediabetic patient with qualifying obesity.

The clinical bottom line: if your prescriber is willing to prescribe semaglutide for your prediabetes, ask whether you qualify for Wegovy under the chronic weight management indication. If you do, Wegovy is the on-label product with the higher labeled maximum dose (2.4 mg vs 2.0 mg) and the cleaner insurance and regulatory path. Off-label Ozempic is a self-pay decision, not an insurance-covered shortcut to prediabetes treatment.

Foundayo + Saxenda + Zepbound as weight-management alternatives

Wegovy is not the only FDA-approved chronic weight management option for prediabetic adults who meet the BMI criteria. Three active alternatives in 2026:

• Foundayo (orforglipron, Eli Lilly) — FDA- approved in 2025 as a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management in adults with BMI 30 or above, or BMI 27 or above with weight-related comorbidity. The ATTAIN-1 pivotal trial reported mean −11.1% body-weight reduction at week 72 on the highest dose versus −2.4% placebo^[9]. LillyDirect Self Pay lists Foundayo at $149 per month — the cheapest on-label branded GLP-1 path currently available. No injection, no refrigeration, no cold-chain pharmacy logistics. See the full Foundayo evidence review for trial detail, dose ladder, and side-effect rates.
• Saxenda (liraglutide 3.0 mg daily, Novo Nordisk) — First FDA-approved GLP-1 for chronic weight management (2014), once-daily subcutaneous injection. Weight-loss magnitude is lower than semaglutide or tirzepatide (typical −5 to −8% at one year), but Saxenda is the longest-studied GLP-1 weight-management option, has the same BMI plus comorbidity eligibility framework, and is now generically available as biosimilar liraglutide following Novo Nordisk patent expiration.
• Zepbound (tirzepatide, Eli Lilly) — FDA- approved in 2023 for chronic weight management; dual GIP/GLP-1 agonist with higher weight-loss magnitude than semaglutide in head-to-head trials (SURMOUNT-5 reported tirzepatide −20.2% vs semaglutide −13.7% at 72 weeks). Same BMI plus comorbidity eligibility framework. LillyDirect Self Pay lists Zepbound vials at $349-$499 per month depending on dose.

For prediabetic adults with qualifying obesity, all three sit on the same FDA chronic-weight-management indication framework as Wegovy. The choice between them is typically driven by cost (Foundayo $149/mo on LillyDirect is the cheapest branded option), route preference (oral tablet vs subcutaneous injection vs single-use injection pen), and insurance formulary preferences when coverage exists. For the full landscape including compounded alternatives, see Wegovy alternatives in 2026 and the full GLP-1 medication reference.

Insurance reality: Ozempic for prediabetes won’t be covered

Insurance coverage for any GLP-1 prescription depends on three things: the drug, the diagnosis code on the claim, and the plan’s formulary rules for that combination. For prediabetic adults, the practical reality breaks down as follows:

• Ozempic for prediabetes: Almost universally denied. PBMs require ICD-10 E11.x (type 2 diabetes) for Ozempic approval. R73.03 (prediabetes) does not satisfy the on-label-indication requirement. Even with prior authorization, plans rarely override for off-label prediabetes use.
• Wegovy for chronic weight management: Variable. Many commercial plans exclude anti-obesity medications entirely. Plans that do cover Wegovy typically require documented BMI of 30+ (or 27+ with comorbidity), prior authorization, often step therapy (failed lifestyle intervention or failed phentermine), and ongoing documentation of at least 5% weight loss at 6 months to continue authorization. Medicare does not cover anti-obesity drugs by statute — but Wegovy is covered under Medicare Part D since the 2024 CV indication expansion for adults with established CV disease and obesity. For more, see the cheapest GLP-1 without insurance buyer guide.
• NovoCare Pharmacy self-pay: Both Wegovy and Ozempic are listed at $499 per month for cash-pay patients via NovoCare. This is the most predictable access path when insurance denies, but it is not insurance coverage — it is direct-pay through the manufacturer’s captive pharmacy.
• LillyDirect Self Pay for Foundayo: Orforglipron (Foundayo) is listed at $149 per month via Eli Lilly’s LillyDirect Self Pay Pharmacy, oral once-daily. For prediabetic adults who meet the BMI criteria, this is the cheapest on-label branded GLP-1 path in the US.
• DPP lifestyle program: Covered without cost- sharing by Medicare (Medicare Diabetes Prevention Program benefit) and by most commercial plans. The cheapest, most evidence-supported first-line intervention.

What to ask your prescriber

If you have prediabetes and are exploring GLP-1 options, walk into the visit with these five questions:

1. What is my measured BMI today, and do I meet the FDA chronic-weight-management criteria? Wegovy and Foundayo require BMI 30 or above, or 27 or above with a weight-related comorbidity. Prediabetes itself can be documented as a weight-related comorbidity at the 27-29.9 BMI bracket by many prescribers. The GLP-1 BMI eligibility calculator walks through the FDA criteria with your specific numbers.
2. Have we exhausted the Diabetes Prevention Program? Most clinical practice guidelines recommend at least one structured trial of intensive lifestyle intervention before escalating to pharmacologic therapy for prediabetes. The CDC-recognized DPP curriculum is covered without cost-sharing by Medicare and most commercial plans.
3. Does my insurance cover Wegovy under the chronic- weight-management benefit, and what prior authorization is required? Your prescriber’s office can usually run a benefits investigation; alternatively, call your insurer’s member services line and ask whether Wegovy is on formulary, what tier, what BMI documentation is required, and whether step therapy applies.
4. If insurance denies, am I a candidate for self-pay options? NovoCare Pharmacy lists Wegovy at $499 per month; LillyDirect Self Pay lists Foundayo at $149 per month. Both are legitimate manufacturer-direct pharmacy channels.
5. What is the plan if I tolerate semaglutide poorly? Many patients have difficulty with semaglutide’s GI side effects at the maintenance dose. Alternatives include orforglipron (Foundayo, oral, daily), tirzepatide (Zepbound, subcutaneous, weekly), and liraglutide (Saxenda, subcutaneous, daily). Discuss the back-up plan before starting, not after a difficult titration.

If you need help locating an obesity-medicine or endocrinology-trained prescriber, see the how to find a GLP-1 prescriber near you guide.

Bottom line

• Ozempic is not FDA-approved for prediabetes. The label covers type 2 diabetes glycemic control and CV risk reduction in T2D adults with established CV disease. Prescribing Ozempic for prediabetes is off-label and almost always uninsured.
• Wegovy may be the on-label semaglutide path. Prediabetic adults with BMI 30+ (or 27+ with weight-related comorbidity, which can include prediabetes itself) qualify for Wegovy under the chronic weight management indication.
• The Diabetes Prevention Program is the gold-standard first line. 58% reduction in T2D incidence at 2.8 years, 34% reduction at 10 years — covered by Medicare and most commercial plans.
• STEP-1 post-hoc data are encouraging but secondary. 84.1% of semaglutide-treated prediabetic participants shifted to normoglycemia at 68 weeks. Hypothesis-generating, not a regulatory-grade prediabetes-prevention claim.
• Foundayo at $149/mo is the cheapest on-label alternative. Eli Lilly’s oral orforglipron, FDA- approved 2025 for chronic weight management on the same BMI plus comorbidity framework as Wegovy.

Frequently asked questions

Related research

• Wegovy vs Ozempic evidence review — the regulatory, dosing, and insurance distinctions between the same molecule under two FDA labels.
• Full GLP-1 medication list reference — every FDA-approved GLP-1 with brand, manufacturer, indication, dose ladder, and DailyMed SetID links.
• What is orforglipron (Foundayo)? — Eli Lilly’s once-daily oral GLP-1, FDA-approved 2025 for chronic weight management.
• Wegovy alternatives in 2026 — the full post-shortage landscape for patients who cannot access brand Wegovy.
• How to find a GLP-1 prescriber near you — the four legitimate access paths plus telehealth verification checklist.
• Cheapest GLP-1 without insurance buyer guide — NovoCare, LillyDirect, manufacturer copay programs, and compounded options compared by total cost.
• GLP-1 BMI eligibility calculator — check whether you meet the FDA criteria for Wegovy, Zepbound, Saxenda, or Foundayo.

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. Ozempic and Wegovy are prescription medications with FDA boxed warnings and contraindications. Prediabetes management decisions involving any GLP-1 medication must be made with a licensed prescriber who has reviewed the full FDA prescribing information and the individual patient’s history. Every regulatory claim in this article is anchored to a primary source (DailyMed or PubMed) and the CDC National Diabetes Statistics Report. Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.